Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C.C. Liu, Holly K. Koblish, Liangxing Wu, et al.
PLoS ONE (2020) Vol. 15, Iss. 4, pp. e0231877-e0231877
Open Access | Times Cited: 141

Showing 1-25 of 141 citing articles:

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, et al.
Cancer Discovery (2020) Vol. 11, Iss. 2, pp. 326-339
Open Access | Times Cited: 212
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1047-1131
Open Access | Times Cited: 196
Pemigatinib: First Approval
Sheridan M. Hoy
Drugs (2020) Vol. 80, Iss. 9, pp. 923-929
Closed Access | Times Cited: 182
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
Vivek Subbiah, Nicholas Iannotti, Martin Gutierrez, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 522-533
Open Access | Times Cited: 150
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Tanios Bekaii‐Saab, Juan W. Valle, Eric Van Cutsem, et al.
Future Oncology (2020) Vol. 16, Iss. 30, pp. 2385-2399
Open Access | Times Cited: 141
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 137
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, et al.
Cancer Treatment Reviews (2023) Vol. 115, pp. 102530-102530
Closed Access | Times Cited: 109
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 47
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 21
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 317-324
Open Access | Times Cited: 84
Combinatorial therapy in tumor microenvironment: Where do we stand?
Smita Kumari, Dia Advani, Sudhanshu Sharma, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188585-188585
Closed Access | Times Cited: 83
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 609-617
Open Access | Times Cited: 68
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
Qibiao Wu, Yuanli Zhen, Lei Shi, et al.
Cancer Discovery (2022) Vol. 12, Iss. 5, pp. 1378-1395
Open Access | Times Cited: 63
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Liangxing Wu, Colin Zhang, Chunhong He, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10666-10679
Closed Access | Times Cited: 58
Targeting Gatekeeper Mutations for Kinase Drug Discovery
Yang Zhou, Shuang Xiang, Fang Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 23, pp. 15540-15558
Closed Access | Times Cited: 39
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 39
Clinical development and management of adverse events associated with FGFR inhibitors
Vivek Subbiah, Srđan Verstovšek
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101204-101204
Open Access | Times Cited: 33
Distinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury
Natalia A. Veniaminova, Yunlong Jia, Adrien M. Hartigan, et al.
Cell Reports (2023) Vol. 42, Iss. 9, pp. 113121-113121
Open Access | Times Cited: 30
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors
Sarina A. Piha‐Paul, Binghe Xu, Ecaterina E. Dumbrava, et al.
The Oncologist (2024) Vol. 29, Iss. 4, pp. e514-e525
Open Access | Times Cited: 15
Coordinated inheritance of extrachromosomal DNAs in cancer cells
King L. Hung, Matthew G. Jones, Ivy Tsz-Lo Wong, et al.
Nature (2024) Vol. 635, Iss. 8037, pp. 201-209
Open Access | Times Cited: 14
A Comprehensive Review of Current Approaches in Bladder Cancer Treatment
Soniya Kumbham, Kazi Md Mahabubur Rahman, Barbara A. Foster, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 2, pp. 286-307
Closed Access | Times Cited: 1
Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2
Guangyan Du, Jie Jiang, Qibiao Wu, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 29, pp. 15905-15911
Open Access | Times Cited: 43
Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway
Zengli Liu, Jialiang Liu, Tianli Chen, et al.
Oncogene (2022) Vol. 41, Iss. 20, pp. 2885-2896
Closed Access | Times Cited: 35
Page 1 - Next Page

Scroll to top